Pharmacovigilance Activities in the Treatment of COVID-19
Q4 Pharmacology, Toxicology and Pharmaceutics
O. Gizem, I. Bilge, S. Sezen, D. N. Hilal, T. Gizem, A. Eda, E. Gozdenur, G. Ali
{"title":"Pharmacovigilance Activities in the Treatment of COVID-19","authors":"O. Gizem, I. Bilge, S. Sezen, D. N. Hilal, T. Gizem, A. Eda, E. Gozdenur, G. Ali","doi":"10.52794/hujpharm.903721","DOIUrl":null,"url":null,"abstract":"The unexpected pandemic initiated by the new coronavirus 2019 (2019-nCoV) caused severe panic among people around the world since December 2019. Coronavirus disease 2019 (COVID-19) has wreaked havoc, and Health Authorities have started to make announcements and studies have been started quickly, for effective treatment and vaccination. In studies, drugs that reduce the symptoms of COVID-19 and alleviate the course of the disease have been used. In addition to the effects of these promising drugs, adverse events and multiple drug interactions have begun to appear all over the world, as well as in our country. Therefore, pharmacovigilance is of particular importance during the COVID-19 pandemic. Health authorities have been taking additional actions and measures to carry out adverse effects monitoring and risk minimization activities of drugs. In our study, we have reviewed the measures taken related to COVID-19 in Turkey and around the world along with safety of drugs used to treat COVID-19 and pharmacovigilance activities during the pandemic. © 2021, Hacettepe University, Faculty of Pharmacy. All rights reserved.","PeriodicalId":39138,"journal":{"name":"Hacettepe University Journal of the Faculty of Pharmacy","volume":"74 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hacettepe University Journal of the Faculty of Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52794/hujpharm.903721","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
The unexpected pandemic initiated by the new coronavirus 2019 (2019-nCoV) caused severe panic among people around the world since December 2019. Coronavirus disease 2019 (COVID-19) has wreaked havoc, and Health Authorities have started to make announcements and studies have been started quickly, for effective treatment and vaccination. In studies, drugs that reduce the symptoms of COVID-19 and alleviate the course of the disease have been used. In addition to the effects of these promising drugs, adverse events and multiple drug interactions have begun to appear all over the world, as well as in our country. Therefore, pharmacovigilance is of particular importance during the COVID-19 pandemic. Health authorities have been taking additional actions and measures to carry out adverse effects monitoring and risk minimization activities of drugs. In our study, we have reviewed the measures taken related to COVID-19 in Turkey and around the world along with safety of drugs used to treat COVID-19 and pharmacovigilance activities during the pandemic. © 2021, Hacettepe University, Faculty of Pharmacy. All rights reserved.
COVID-19治疗中的药物警戒活动
2019年12月以来,新型冠状病毒2019 (2019- ncov)引发的意外大流行在世界各地引起了严重恐慌。2019冠状病毒病(COVID-19)已经造成严重破坏,卫生当局已经开始发布公告,并迅速启动研究,以进行有效的治疗和疫苗接种。在研究中,已经使用了减轻COVID-19症状和缓解病程的药物。除了这些有前景的药物的作用,不良事件和多种药物相互作用已经开始出现在世界各地,以及在我国。因此,在COVID-19大流行期间,药物警戒尤为重要。卫生当局一直在采取额外行动和措施,开展药物不良影响监测和风险最小化活动。在我们的研究中,我们回顾了土耳其和世界各地采取的与COVID-19相关的措施,以及用于治疗COVID-19的药物的安全性和大流行期间的药物警戒活动。©2021,Hacettepe大学药学院。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。